Breaking News

Vaxcyte, Lonza Partner on Manufacture of Pneumococcal Vax

Aims to establish global commercial manufacturing capacity for Vaxcyte's PCV candidates, VAX-24, and VAX-31.

Vaxcyte, a clinical-stage vaccine innovation company, and Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, entered into a new commercial manufacturing agreement to support the potential global commercialization of Vaxcyte’s PCV candidates, VAX-24 and VAX-31. This agreement complements Vaxcyte’s plans to utilize existing Lonza infrastructure to advance clinical development and the anticipated initial U.S. launch of VAX-24. Lonza will provide Vaxcy...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters